SSTR2 and neuroendocrine neoplasm: 177Lu-DOTATATE treatment targets tumor cells overexpressing the somatostatin receptor type 2 (SSTR2) and is authorized in Europe and the United States as Lutathera (Advanced Accelerator Applications) for therapy of metastasized neuroendocrine tumors (17).